In the TRACER trial , vorapaxar , a protease-activated receptor-1 antagonist , plus standard care in non-ST-segment elevation acute coronary syndrome ( NSTE ACS ) patients did not significantly reduce the primary composite end point but reduced a key secondary end point and significantly increased bleeding .